Financials data is unavailable for this security.
View more
Year on year Pure Biologics SA 's revenues fell -85.65% from 662.00k to 95.00k. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 25.60m to a larger loss of 35.69m.
Gross margin | -2,439.13% |
---|---|
Net profit margin | -48,734.78% |
Operating margin | -43,546.38% |
Return on assets | -72.94% |
---|---|
Return on equity | -250.95% |
Return on investment | -99.86% |
More ▼
Cash flow in PLNView more
In 2023, Pure Biologics SA increased its cash reserves by 59.63%, or 1.35m. Cash Flow from Financing totalled 24.22m or 25,492.63% of revenues. In addition the company used 23.26m for operations while cash from investing totalled 391.00k.
Cash flow per share | -8.96 |
---|---|
Price/Cash flow per share | -- |
Book value per share | -0.9246 |
---|---|
Tangible book value per share | -0.9913 |
More ▼
Balance sheet in PLNView more
Current ratio | 2.07 |
---|---|
Quick ratio | -- |
Total debt/total equity | -- |
---|---|
Total debt/total capital | 1.30 |
More ▼